Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by the absence of dystrophin, a sarcolemmal protein which links the cytoskeleton to the extracellular matrix by interacting with a large number of proteins. Heart failure is a classic complication of this disease. The authors review the pathogenesis and therapeutics of cardiac involvement in DMD.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Biomarkers / metabolism
-
Cardiac Pacing, Artificial / methods
-
Cardiomyopathies / etiology
-
Cardiomyopathies / genetics*
-
Cardiomyopathies / metabolism
-
Cardiomyopathies / therapy*
-
Drug Therapy, Combination
-
Dystrophin / biosynthesis
-
Dystrophin / genetics
-
Genetic Therapy / methods
-
Heart Failure / etiology
-
Heart Failure / genetics*
-
Heart Failure / metabolism
-
Heart Failure / therapy*
-
Humans
-
Muscular Dystrophy, Duchenne / complications
-
Muscular Dystrophy, Duchenne / genetics*
-
Muscular Dystrophy, Duchenne / metabolism
-
Muscular Dystrophy, Duchenne / therapy*
-
Practice Guidelines as Topic
-
Prognosis
-
Stem Cell Transplantation / methods
-
Ventricular Function, Left / drug effects
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Biomarkers
-
Dystrophin